Investigating the effects of prednisolone on behavior in mouse models of Duchenne muscular dystrophy

Minou Verhaeg,D. van de Vijver,C.L. Tanganyika de Winter,E.M. van der Pijl,L.J.M. Mastenbroek,U. Leka,T.L. Stan,M. van Putten

DOI: https://doi.org/10.1101/2024.10.29.620838

2024-10-29

Abstract:Background: Next to progressive muscle loss, Duchenne muscular dystrophy patients suffer from behavioral and cognitive problems. This is due to mutations in the DMD gene, that result in the lack of dystrophin in both the muscles and brain. As part of the standards of care, patients receive corticosteroids (prednisolone or deflazacort) to slow down muscle degeneration. The precise consequences of chronic corticosteroid usage on the behavior of DMD patients remain unclear, mainly due to challenges of recruiting corticosteroid naïve patients into clinical studies. Objective: This study used DMD mouse models, representing mutations resulting in lack of one or more dystrophin isoforms, to analyze the effects of corticosteroid treatment on different behavioral domains. Methods: Prednisolone (PDN) or placebo was administered via a subcutaneous 60-day slow release pellet (66 μg/day) and mice were subjected to several behavioral tests. Results: Unfortunately, the pellet only exposed mice to PDN for half of the intended duration. During the time of PDN exposure, we found a small amelioration in anxiety but were unable to find any differences in social interaction and spatial learning and memory. Conclusions: Short term exposure to PDN via a slow release pellet does not seem to negatively affect anxiety, social interaction or spatial learning and memory. We cannot rule out that a longer treatment period than 4 weeks would affect behavior in DMD mice.

Animal Behavior and Cognition

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the effects of corticosteroids (especially prednisolone) on the behavior of Duchenne Muscular Dystrophy (DMD) mouse models. Specifically, the researchers used DMD mouse models representing different mutation types (resulting in the absence of one or more dystrophin subtypes) and analyzed the specific effects of corticosteroid treatment on different behavioral domains. The research background indicates that in addition to progressive muscle loss, DMD patients also suffer from behavioral and cognitive problems, which are related to mutations in the DMD gene, and these mutations lead to a lack of dystrophin in muscles and the brain. As part of the standard of care, patients receive corticosteroid (such as prednisolone or deflazacort) treatment to slow down muscle degeneration, but the specific consequences of long - term corticosteroid use on the behavior of DMD patients are still unclear, mainly because it is difficult to recruit patients who have not received corticosteroid treatment to participate in clinical studies. Therefore, this study aims to fill this knowledge gap through DMD mouse models.